The novel gene therapy using adeno-associated viral vector mediatedMDA7/IL-24 for human pancreatic cancer
Project/Area Number |
22591444
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
General surgery
|
Research Institution | Nippon Medical School |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
MIYAKE Kouichi 日本医科大学, 医学部, 准教授 (90267211)
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Keywords | 膵癌 / 遺伝子治療 / MDA7/IL-24 / gemcitabine / MDA7/IL24 |
Research Abstract |
We established a orthotropic pancreatic cancer model in hamsters using the pancreatic cancer cell line, PGHAM-1 and generated adeno-associated viral vector expressing MDA7/IL-24. The survival time both in the gene therapy alone and in the gene therapy plus gemcitabine group was longer than that in the control group. There were no detectable side effects. This novel gene therapy is a potentially effective treatment for pancreatic cancer although further studies are needed in the near future.
|
Report
(4 results)
Research Products
(62 results)